{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:17:15Z","timestamp":1787847435798,"version":"build-2784847793"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Oncolytic viruses are currently the subject of cancer treatment research. Unlike other viruses, they can target tumor cells while avoiding healthy ones. The vesicular stomatitis virus (VSV) has the ability to kill tumor cells through one of two different apoptotic pathways, depending on which cell line is being studied. Even when no other viral components are present, the VSV matrix protein can induce cell death in HeLa cells through apoptosis. The purpose of this research was to examine the similarities and differences in the induction of cell death by native and mutant VSV matrix proteins.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>To create the mutant VSV matrix protein, the amino acid Ser was substituted with Lys at residue 89 (S89K). After the matrix gene was cloned into the expression vector, both the normal and mutant versions were transfected into HeLa cells. The expression was verified by fluorescence microscopy, and flow cytometry was used to evaluate the apoptosis rate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>After 48 hours of transfection, the VSV matrix protein was found to promote cell death at the highest level. The results showed that once basic amino acids were substituted with alcoholic ones in the S89K mutant, the apoptotic activity of the VSV matrix protein was enhanced.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This study discovered that increasing apoptosis induction by introducing a specific mutation at a specific location in the VSV matrix protein improved its apoptotic capabilities. The ability to engineer recombinant viruses with specific mutations is crucial for the development of cancer vaccines that target specific cell lines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/abr.abr_327_25","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T11:00:15Z","timestamp":1780138815000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Oncolytic Effects of S89K Matrix Protein of Vesicular Stomatitis Virus in Cervical Cancer"],"prefix":"10.4103","volume":"15","author":[{"given":"Mehdi","family":"Ajorloo","sequence":"first","affiliation":[{"name":"Biological Products and Blood Safety Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashkan","family":"Alamdary","sequence":"additional","affiliation":[{"name":"Research and Development Department, Production and Research Complex, Pasteur Institute of Iran, Karaj, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Samaie","sequence":"additional","affiliation":[{"name":"Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Arabi Mianroodi","sequence":"additional","affiliation":[{"name":"Research and Development Department, Production and Research Complex, Pasteur Institute of Iran, Karaj, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behzad","family":"Esfandiari","sequence":"additional","affiliation":[{"name":"Animal Sciences Unit, Production and Research Complex, Pasteur Institute of Iran, Karaj, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed M","family":"Hasanzadeh","sequence":"additional","affiliation":[{"name":"Research and Development Department, Production and Research Complex, Pasteur Institute of Iran, Karaj, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Gholami","sequence":"additional","affiliation":[{"name":"Research and Development Department, Production and Research Complex, Pasteur Institute of Iran, Karaj, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,3]]},"reference":[{"key":"R1-20260530","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","article-title":"Oncolytic virotherapy: Basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"R2-20260530","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/bs.ircmb.2023.05.001","article-title":"Oncolytic viruses in hematological malignancies: Hijacking disease biology and fostering new promises for immune and cell-based therapies","volume":"379","author":"Sousa-Pimenta","year":"2023","journal-title":"Int Rev Cell Mol Biol"},{"key":"R3-20260530","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/neuonc\/not310","article-title":"Glioma virus therapies between bench and bedside","volume":"16","author":"Kaufmann","year":"2014","journal-title":"Neuro Oncol"},{"key":"R4-20260530","doi-asserted-by":"crossref","first-page":"229","DOI":"10.5501\/wjv.v10.i5.229","article-title":"Oncolytic virus therapy in cancer: A current review","volume":"10","author":"Santos Apolonio","year":"2021","journal-title":"World J Virol"},{"key":"R5-20260530","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","article-title":"Exploring treatment options in cancer: Tumor treatment strategies","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"R6-20260530","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2217\/fvl-2016-0129","article-title":"Designing and building oncolytic viruses","volume":"12","author":"Maroun","year":"2017","journal-title":"Future Virol"},{"key":"R7-20260530","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1099\/vir.0.046672-0","article-title":"Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer","volume":"93","author":"Hastie","year":"2012","journal-title":"J Gen Virol"},{"key":"R8-20260530","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s44337-024-00082-y","article-title":"Unlocking the potential: A specific focus on vesicular stomatitis virus as a promising oncolytic and immunomodulatory agent in cancer therapy","volume":"1","author":"Elnosary","year":"2024","journal-title":"Discover Med"},{"key":"R9-20260530","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1089\/hum.2024.002","article-title":"Matrix protein of vesicular stomatitis virus targets the mitochondria, reprograms glucose metabolism, and sensitizes to 2deoxyglucose in glioblastoma","volume":"35","author":"Zhou","year":"2024","journal-title":"Hum Gene Ther"},{"key":"R10-20260530","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3390\/v10020090","article-title":"Oncotargeting by vesicular stomatitis virus (VSV): Advances in cancer therapy","volume":"10","author":"Bishnoi","year":"2018","journal-title":"Viruses"},{"key":"R11-20260530","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1158\/1078-0432.CCR-11-3149","article-title":"Molecular pathways: Multimodal cancer-killing mechanisms employed by oncolytic vesiculoviruses","volume":"19","author":"Mahoney","year":"2013","journal-title":"Clin Cancer Res"},{"key":"R12-20260530","doi-asserted-by":"crossref","first-page":"e1000251","DOI":"10.1371\/journal.ppat.1000251","article-title":"Rhabdovirus matrix protein structures reveal a novel mode of self-association","volume":"4","author":"Graham","year":"2008","journal-title":"PLoS Pathog"},{"key":"R13-20260530","doi-asserted-by":"crossref","first-page":"9897","DOI":"10.1128\/JVI.00761-10","article-title":"Two overlapping domains of a lyssavirus matrix protein that acts on different cell death pathways","volume":"84","author":"Larrous","year":"2010","journal-title":"J Virol"},{"key":"R14-20260530","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1128\/JVI.02651-07","article-title":"Mitochondrial dysfunction in lyssavirus-induced apoptosis","volume":"82","author":"Gholami","year":"2008","journal-title":"J Virol"},{"key":"R15-20260530","doi-asserted-by":"crossref","first-page":"W174","DOI":"10.1093\/nar\/gkv342","article-title":"I-TASSER server: New development for protein structure and function predictions","volume":"43","author":"Yang","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"R16-20260530","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/s41587-023-01773-0","article-title":"Fast and accurate protein structure search with Foldseek","volume":"42","author":"van Kempen","year":"2024","journal-title":"Nat Biotechnol"},{"key":"R17-20260530","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/cas.13027","article-title":"Oncolytic virus therapy: A new era of cancer treatment at dawn","volume":"107","author":"Fukuhara","year":"2016","journal-title":"Cancer Sci"},{"key":"R18-20260530","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3390\/biomedicines5010008","article-title":"Oncolytic vesicular stomatitis virus as a viroimmunotherapy: Defeating cancer with a \u201chammer\u201cand \u201canvil\u201c","volume":"5","author":"Melzer","year":"2017","journal-title":"Biomedicines"},{"key":"R19-20260530","first-page":"150845","article-title":"Apoptosis and molecular targeting therapy in cancer","author":"Hassan","year":"2014","journal-title":"Biomed Res Int. 2014"},{"key":"R21-20260530","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1365-2184.2012.00845.x","article-title":"Programmed cell death pathways in cancer: A review of apoptosis, autophagy and programmed necrosis","volume":"45","author":"Ouyang","year":"2012","journal-title":"Cell Prolif"},{"key":"R22-20260530","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ebiom.2016.06.046","article-title":"Oncolytic viruses: Therapeutics with an identity crisis","volume":"9","author":"Breitbach","year":"2016","journal-title":"EBioMedicine"},{"key":"R23-20260530","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.ymthe.2017.03.026","article-title":"Oncolytic virotherapy: A contest between apples and oranges","volume":"25","author":"Russell","year":"2017","journal-title":"Mol Ther"},{"key":"R24-20260530","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40425-016-0158-5","article-title":"Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy","volume":"4","author":"Rehman","year":"2016","journal-title":"J Immunother Cancer"},{"key":"R25-20260530","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40265-023-01846-z","article-title":"Nadofaragene firadenovec: First approval","volume":"83","author":"Lee","year":"2023","journal-title":"Drugs"},{"key":"R26-20260530","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/CMR.0000000000000180","article-title":"Adapted ECHO 7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study","volume":"25","author":"Doni\u0146a","year":"2015","journal-title":"Melanoma Res"},{"key":"R27-20260530","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.3390\/v15122378","article-title":"Evolving horizons: Adenovirus vectors'timeless influence on cancer, gene therapy and vaccines","volume":"15","author":"Trivedi","year":"2023","journal-title":"Viruses"},{"key":"R28-20260530","first-page":"166538","article-title":"Vesicular stomatitis virus sensitizes immunologically cold tumors to checkpoint blockade by inducing pyroptosis","author":"Lin","year":"1868","journal-title":"Biochim Biophys Acta Mol Basis Dis. 2022"},{"key":"R29-20260530","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.3390\/cancers13092199","article-title":"Viral proteins as emerging cancer therapeutics","volume":"13","author":"Manocha","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R30-20260530","doi-asserted-by":"crossref","first-page":"249","DOI":"10.31557\/APJCP.2021.22.1.249","article-title":"The role of vesicular stomatitis virus matrix protein in autophagy in the breast cancer","volume":"22","author":"Askari","year":"2021","journal-title":"Asian Pac J Cancer Prev"},{"key":"R31-20260530","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1007\/s11033-019-04799-3","article-title":"M51R and Delta-M51 matrix protein of the vesicular stomatitis virus induce apoptosis in colorectal cancer cells","volume":"46","author":"Gray","year":"2019","journal-title":"Mol Biol Rep"},{"key":"R32-20260530","doi-asserted-by":"crossref","first-page":"12169","DOI":"10.1128\/JVI.75.24.12169-12181.2001","article-title":"Matrix protein and another viral component contribute to induction of apoptosis in cells infected with vesicular stomatitis virus","volume":"75","author":"Kopecky","year":"2001","journal-title":"J Virol"},{"key":"R33-20260530","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.surg.2012.09.003","article-title":"Variation in susceptibility of human malignant melanomas to oncolytic vesicular stomatitis virus","volume":"153","author":"Blackham","year":"2013","journal-title":"Surgery"},{"key":"R34-20260530","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1128\/JVI.02979-15","article-title":"Abortively infected astrocytes appear to represent the main source of interferon beta in the virusinfected brain","volume":"90","author":"Pfefferkorn","year":"2016","journal-title":"J Virol"}],"container-title":["Advanced Biomedical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/abr.abr_327_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:18:18Z","timestamp":1787843898000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/abr.abr_327_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/abr.abr_327_25","relation":{},"ISSN":["2277-9175"],"issn-type":[{"value":"2277-9175","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"2025-06-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}